CARU The HY pertension in the V ery E lderly T rial – latest data Stephen Jackson Professor of...

28
CARU The The HY HY pertension pertension in the in the V V ery ery E E lderly lderly T T rial – latest data rial – latest data Stephen Jackson Professor of Clinical Gerontology King’s Health Partners

Transcript of CARU The HY pertension in the V ery E lderly T rial – latest data Stephen Jackson Professor of...

Page 1: CARU The HY pertension in the V ery E lderly T rial – latest data Stephen Jackson Professor of Clinical Gerontology King’s Health Partners.

CARU

TheThe HYHYpertensionpertension in the in the VVeryery EElderlylderly TTrial rial

– latest data– latest data

TheThe HYHYpertensionpertension in the in the VVeryery EElderlylderly TTrial rial

– latest data– latest data

Stephen Jackson

Professor of Clinical Gerontology

King’s Health Partners

Page 2: CARU The HY pertension in the V ery E lderly T rial – latest data Stephen Jackson Professor of Clinical Gerontology King’s Health Partners.

CARU

DeclarationsDeclarationsDeclarationsDeclarations

First author – Nigel Beckett – has moved from Imperial College to King’s Health Partners since the NEJM paper was published.

As a PROGRESS investigator, Servier have funded speaking at meetings around 2001-3.

Page 3: CARU The HY pertension in the V ery E lderly T rial – latest data Stephen Jackson Professor of Clinical Gerontology King’s Health Partners.
Page 4: CARU The HY pertension in the V ery E lderly T rial – latest data Stephen Jackson Professor of Clinical Gerontology King’s Health Partners.

Blood Pressure & The Very Elderly (aged 80 or more)

• Population studies suggest better survival with higher levels of blood pressure

• Worse survival reported in hypertensives with SBP levels below 140 mmHg (Oates et al. 2007)

• Clinical trials recruited too few.

• Meta-analysis (n=1670) (Gueyffier et al. 1997) – 36% reduction in the risk of stroke (BENEFIT)– 14% (p=0.05) increase in total mortality (RISK)

• Hypertension in the Very Elderly Trial (HYVET) pilot results (n=1273) similar to meta-analysis (Bulpitt et al. 2003)

Page 5: CARU The HY pertension in the V ery E lderly T rial – latest data Stephen Jackson Professor of Clinical Gerontology King’s Health Partners.

The Trial:International, multi-centre, randomised double-blind placebo controlled

Inclusion Criteria: Exclusion Criteria:Aged 80 or more, Standing SBP < 140mmHgSystolic BP; 160 -199mmHg Stroke in last 6 months+ diastolic BP; <110 mmHg, DementiaInformed consent Need daily nursing care

Primary Endpoint: All strokes (fatal and non-fatal)

Target blood pressure

150/80 mmHg

Page 6: CARU The HY pertension in the V ery E lderly T rial – latest data Stephen Jackson Professor of Clinical Gerontology King’s Health Partners.

Statistical Analysis• Numbers based on a 35% reduction in all strokes

– α= 0.01 ß=0.1– Stroke event rate of 40/1000– 10,500 years of follow-up required

• 3 interim analyses planned– Stopped at 2nd as decrease in stroke and all-cause mortality

• ITT and PP analyses

• Other main trial endpoints: total mortality, cardiovascular mortality, cardiac mortality, stroke mortality, heart failure

Page 7: CARU The HY pertension in the V ery E lderly T rial – latest data Stephen Jackson Professor of Clinical Gerontology King’s Health Partners.

4761 Entered intoPlacebo Run-in

Placebo1912

Active1933

916 not randomised

• 3845 randomised; Western Europe (86) Eastern Europe (2144), China (1526), Australasia (19), Tunisia (70)

• At end of trial; 1882 still in double blind, 17 vital status not known, 220 in open follow-up

Page 8: CARU The HY pertension in the V ery E lderly T rial – latest data Stephen Jackson Professor of Clinical Gerontology King’s Health Partners.

Placebo(n= 1912)

Active(n= 1933)

Age (years) 83.5 83.6

Female 60.3% 60.7%

Blood Pressure:

Sitting SBP (mmHg) 173.0 173.0

Sitting DBP (mmHg) 90.8 90.8

Orthostatic Hypotension‡ 8.8% 7.9%

Isolated Systolic Hypertension 32.6% 32.3%

Baseline data

‡ Fall in SBP ≥ 20mmHg and/or fall in DBP ≥ 10mmHg

Page 9: CARU The HY pertension in the V ery E lderly T rial – latest data Stephen Jackson Professor of Clinical Gerontology King’s Health Partners.

Baseline Data (Previous Cardiovascular History)

Placebo(%)

Active(%)

Cardiovascular disease 12.0 11.5

Known Hypertension 89.9 89.9

Anti-hypertensive treatment 65.1 64.2

Stroke 6.9 6.7

Myocardial Infarction 3.2 3.1

Heart Failure 2.9 2.9

Page 10: CARU The HY pertension in the V ery E lderly T rial – latest data Stephen Jackson Professor of Clinical Gerontology King’s Health Partners.

Placebo Active

Current smoker 6.6% 6.4%

Diabetes

(Known DM/ DM treatment/glucose>11.1mmo/l)

6.9% 6.8%

Total cholesterol (mmol/l) 5.3 5.3

HDL Cholesterol (mmol/l) 1.35 1.35

Serum Creatinine (μmol/l) 89.2 88.6

Uric acid (µmol/l) 279 280

Body Mass Index (kg/m2) 24.7 24.7

Baseline data (Cardiovascular Risk factors)

Page 11: CARU The HY pertension in the V ery E lderly T rial – latest data Stephen Jackson Professor of Clinical Gerontology King’s Health Partners.

Blood pressure separation

70

80

90

100

110

120

130

140

150

160

170

180

0 1 2 3 4 5

Follow-up (years)

Blo

od

Pre

ssu

re (

mm

Hg

)

Placebo

Indapamide SR +/-perindoprilIMedian follow-up 1.8 years

15 mmHg

6 mmHg

Page 12: CARU The HY pertension in the V ery E lderly T rial – latest data Stephen Jackson Professor of Clinical Gerontology King’s Health Partners.

All stroke(30% reduction)

PlaceboIndapamideSR ±perindopril

Indapamide

SR

±perindopril

Placebo

P=0.055

Page 13: CARU The HY pertension in the V ery E lderly T rial – latest data Stephen Jackson Professor of Clinical Gerontology King’s Health Partners.

Total Mortality(21% reduction)

Placebo

Indapamide

SR

±perindopril

P=0.019

PlaceboIndapamideSR ±perindopril

Page 14: CARU The HY pertension in the V ery E lderly T rial – latest data Stephen Jackson Professor of Clinical Gerontology King’s Health Partners.

Fatal Stroke(39% reduction)

Indapamide

SR

±perindopril

Placebo

P=0.046

PlaceboIndapamideSR ±perindopril

Page 15: CARU The HY pertension in the V ery E lderly T rial – latest data Stephen Jackson Professor of Clinical Gerontology King’s Health Partners.

Heart Failure(64% reduction)

P<0.0001

Placebo

IndapamideSR

±perindopril

PlaceboIndapamideSR ±perindopril

Page 16: CARU The HY pertension in the V ery E lderly T rial – latest data Stephen Jackson Professor of Clinical Gerontology King’s Health Partners.

0 20.50.20.1

HR 95% CI

0.70 (0.49, 1.01)

0.61 (0.38, 0.99)

0.79 (0.65, 0.95)

0.81 (0.62, 1.06)

0.77 (0.60, 1.01)

0.71 (0.42, 1.19)

0.36 (0.22, 0.58)

0.66 (0.53, 0.82)

All Stroke

Stroke Death

All cause mortality

NCV/Unknown death

CV Death

Cardiac Death

Heart Failure

CV events

ITT – Summary

Page 17: CARU The HY pertension in the V ery E lderly T rial – latest data Stephen Jackson Professor of Clinical Gerontology King’s Health Partners.

Biochemical Changes from Baseline (2 year cohort)

•In 2 year cohort there were no significant differences between the groups with regard to change in serum….

•Potassium•Uric acid•Glucose•Creatinine

•At 2 years 73.4% on combination treatment in active group (85.2% placebo)

Page 18: CARU The HY pertension in the V ery E lderly T rial – latest data Stephen Jackson Professor of Clinical Gerontology King’s Health Partners.

Safety

Reported serious adverse events (after randomisation)

– 448 in the placebo group vs 358 in active (p=0.001)

– Only 5 categorised by the local investigator possible SADRs (3 in placebo group, 2 being in active)

Page 19: CARU The HY pertension in the V ery E lderly T rial – latest data Stephen Jackson Professor of Clinical Gerontology King’s Health Partners.

CARU

4 centres closed in first year due to data quality uncertainties

Large large number of patients from Eastern Europe and China

Change in shygs (Hg to semiautomatic) Protocol change from DBP 90-109 extended to

DBP<110 after 2 years Trial stopped early due to mortality benefit in active

treatment group. Last visit 8 months later. 2nd interim analysis after 6 years of recruitment RR stroke 0.59 (0.4-0.88) p=0.0009 RR all cause mortality 0.76 (0.62-0.93) p=0.007

Final dataset failed to show primary outcome benefit (all stroke)

Points worthy of commentPoints worthy of commentPoints worthy of commentPoints worthy of comment

Page 20: CARU The HY pertension in the V ery E lderly T rial – latest data Stephen Jackson Professor of Clinical Gerontology King’s Health Partners.

CARU

ApplicabilityApplicabilityApplicabilityApplicability

Page 21: CARU The HY pertension in the V ery E lderly T rial – latest data Stephen Jackson Professor of Clinical Gerontology King’s Health Partners.

CARUCARU

2008 Trial of the Year awarded by ImpACT (Important Achievements of Clinical Trials)

American Heart Association top ten list for major advances in heart disease and stroke research in 2008

testAchievements of HYVET Achievements of HYVET Achievements of HYVET Achievements of HYVET

Page 22: CARU The HY pertension in the V ery E lderly T rial – latest data Stephen Jackson Professor of Clinical Gerontology King’s Health Partners.

CARU

102 reported fractures in 3,845 participants, 90 validated (majority femur) 38 active

52 placebo

Cox proportional hazard regression adjusted for baseline risk factors Point estimate 0.58 (0.33-1.00) p=0.0498

Other findings from HYVET (1)Other findings from HYVET (1)Other findings from HYVET (1)Other findings from HYVET (1)The effect of treatment based on a diuretic (indapamide) ± ACE inhibitor (perindopril) on fractures in the HYVET.

Peters et al Age Ageing 2010 39: 609-616

Page 23: CARU The HY pertension in the V ery E lderly T rial – latest data Stephen Jackson Professor of Clinical Gerontology King’s Health Partners.

CARU

3336 pts mean follow up 2.2 years Baseline and annual MMSE Diagnosis of dementia using standard

criteria MMSE

-1.1 placebo +0.7 active

Dementia Placebo 38 cases/1000 pt years Active 33 cases/1000 pt years

HYVET-COG

Other findings from HYVET (2)Other findings from HYVET (2)Other findings from HYVET (2)Other findings from HYVET (2)

Peters et al 2008 Lancet Neurology 7: 683-689.

Page 24: CARU The HY pertension in the V ery E lderly T rial – latest data Stephen Jackson Professor of Clinical Gerontology King’s Health Partners.

CARU

2656 pts completed a GDS-15 GDS ≥ 6 associated with

risk of all cause mortality HR 1.8 (1.4 – 2.3)

CV mortality HR 2.1 (1.5 – 3.0)

All stroke HR 1.8 (1.2 – 2.8)

CV events HR 1.6 (1.2 – 2.1) Each point on GDS at baseline associated with

significantly increased risk of fatal and non fatal CV events, all cause mortality and dementia.

Depression:

Other findings from HYVET (3)Other findings from HYVET (3)Other findings from HYVET (3)Other findings from HYVET (3)

Peters et al 2010 Age Ageing 39: 439-445

Page 25: CARU The HY pertension in the V ery E lderly T rial – latest data Stephen Jackson Professor of Clinical Gerontology King’s Health Partners.

CARU

Antihypertensive treatment based on indapamide (SR) 1.5mg (± perindopril) reduced stroke mortality and total mortality in a very elderly cohort.

NNT (2 years) = 94 for stroke and 40 for mortality Large and significant benefit in reduction of heart

failure events and for combined endpoint of cardiovascular events

Benefits seen early Treatment regimen was safe Protocol target of <150/80 mmHg

reached in 20% on placebo; 48% on active treatment ISH target reached in 71% (J Hum Hypertens 2011)

ConclusionsConclusionsConclusionsConclusions

Page 26: CARU The HY pertension in the V ery E lderly T rial – latest data Stephen Jackson Professor of Clinical Gerontology King’s Health Partners.

CARU

Page 27: CARU The HY pertension in the V ery E lderly T rial – latest data Stephen Jackson Professor of Clinical Gerontology King’s Health Partners.

CARU

Page 28: CARU The HY pertension in the V ery E lderly T rial – latest data Stephen Jackson Professor of Clinical Gerontology King’s Health Partners.

Per-Protocol

HR 95% CI P

All stroke - 34% 0.46 - 0.95 0.025

Total mortality - 28% 0.59 - 0.88 0.001

Fatal stroke - 45% 0.33 - 0.93 0.021

Cardiovascular mortality

-27% 0.55-0.97 0.029

Heart failure -72% 0.17-0.48 <0.001

Cardiovascular events - 37% 0.51-0.71 <0.001